Out-of-clinic and self-managed abortion in Bangladesh: menstrual regulation provider perspectives

被引:15
|
作者
Crouthamel, Bonnie [1 ]
Pearson, Erin [2 ]
Tilford, Sarah [1 ]
Hurst, Samantha [3 ]
Paul, Dipika [4 ]
Aqtar, Fahima [4 ]
Silverman, Jay [5 ]
Averbach, Sarah [1 ,5 ]
机构
[1] Univ Calif San Diego, Dept Obstet Gynecol & Reprod Sci, 9300 Campus Point Dr, San Diego, CA 92037 USA
[2] Ipas, POB 9990, Chapel Hill, NC 27515 USA
[3] Univ Calif San Diego, Dept Family Med & Publ Hlth, 9500 Gilman Dr 0507, San Diego, CA 92093 USA
[4] Ipas Bangladesh, Flat B2 & C2,2nd Floor,House 2F-1-3,Mymensingh Rd, Dhaka 1000, Bangladesh
[5] Univ Calif San Diego, Sch Med, Ctr Gender Equ Hlth, 9500 Gilman Dr 0507, San Diego, CA 92093 USA
关键词
Abortion; Menstrual regulation; Family planning;
D O I
10.1186/s12978-021-01123-w
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background In Bangladesh, abortion is illegal except to save a woman's life, though menstrual regulation (MR) is permitted. MR involves the use of manual uterine aspiration or Misoprostol (with or without Mifepristone) to induce menstruation up to 10-12 weeks from the last menstrual period. Despite the availability of safe and legal MR services, abortions still occur in informal setttings and are associated with high complication rates, causing women to then seek post abortion care (PAC). The objective of this study is to contextualize MR in Bangladesh and understand systemic barriers to seeking care in formal settings and faciltators to seeking care in informal settings via the perspective of MR providers in an effort to inform interventions to improve MR safety. Methods Qualitative individual semi-structured interviews were conducted with 25 trained MR providers (doctors and nurses) from urban tertiary care facilities in six different cities in Bangladesh from April to July, 2018. Interviews explored providers' knowledge of MR and abortion in Bangladesh, knowledge/experience with informal MR providers, knowledge/experience with patients attempting self-managed abortion, personal attitudes and moral perspectives of MR/abortion in general, and barriers to formal MR. Team based coding and a directed content analysis approach was performed by three researchers. Results There were three predominant yet overlapping themes: (i) logistics of obtaining MR/PAC/abortion, (ii) provider attitudes, and (iii) overcoming barriers to safe MR. With regards to logistics, lack of consensus among providers revealed challenges with defining MR/abortion gestational age cutoffs. Increasing PAC services may be due to patients purchasing Mifepristone/Misoprostol from pharmacists who do not provide adequate instruction about use, but are logistically easier to access. Patients may be directed to untrained providers by brokers, who intercept patients entering the hospitals/clinics and receive a commission from informal clinics for bringing patients. Provider attitudes and biases about MR can impact who receives care, creating barriers to formal MR for certain patients. Attitudes to MR in informal settings was overwhelmingly negative, which may contribute to delays in care-seeking and complications which endanger patients. Perceived barriers to accessing formal MR include distance, family influence, brokers, and lack of knowledge. Conclusions Lack of standardization among providers of MR gestational age cutoffs may affect patient care and MR access, causing some patients to be inappropriately turned away. Providers in urban tertiary care facilities in Bangladesh see primarily the complicated MR/PAC cases, which may impact their negative attitude, and the safety of out-of-clinic/self-managed abortion is unknown. MR safety may be improved by eliminating brokers. A harm reduction approach to improve counseling about MR/abortion care in pharmacies may improve safety and access. Policy makers should consider increasing training of frontline health workers, such as Family Welfare Visitors to provide evidence-based information about Mifepristone/Misoprostol.
引用
收藏
页数:12
相关论文
共 50 条
  • [11] Patient and Provider Perspectives on Self-Managed Pessary Care: A Qualitative Study of Canadian Patients at a Tertiary Urogynaecology Clinic
    Stairs, J.
    Gujral, P.
    Ehlebracht, A.
    Van Diepen, A.
    Clancy, A. A.
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2023, 34 : S157 - S157
  • [12] Complications of Unsafe and Self-Managed Abortion
    Harris, Lisa H.
    Grossman, Daniel
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (11): : 1029 - 1040
  • [13] Self-Managed Abortion in the United States
    Verma, Nisha
    Grossman, Daniel
    CURRENT OBSTETRICS AND GYNECOLOGY REPORTS, 2023, 12 (02) : 70 - 75
  • [14] Self-Managed Abortion in the United States
    Nisha Verma
    Daniel Grossman
    Current Obstetrics and Gynecology Reports, 2023, 12 : 70 - 75
  • [15] Self-managed abortion: A systematic scoping review
    Moseson, Heidi
    Herold, Stephanie
    Filippa, Sofia
    Barr-Walker, Jill
    Baum, Sarah E.
    Gerdts, Caitlin
    BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2020, 63 : 87 - 110
  • [16] Self-managed Medication Abortion in the United States
    Jung, Christina
    Nippita, Siripanth
    CLINICAL OBSTETRICS AND GYNECOLOGY, 2023, 66 (04): : 739 - 748
  • [17] Prosecutorial Discretion for Self-Managed Abortion Helpers
    Skuster, Patty
    JOURNAL OF LAW MEDICINE & ETHICS, 2023, 51 (03): : 565 - 569
  • [18] SELF-MANAGED ABORTION IN THE LITERATURE: A SYSTEMATIC REVIEW
    Moseson, H.
    Herold, S.
    Filippa, S.
    Barr-Walker, J.
    Baum, S.
    Gerdts, C.
    CONTRACEPTION, 2019, 100 (04) : 316 - 316
  • [19] Medical Assessment After Self-Managed Abortion
    Wetterer, Libby
    Shenko, Christina
    Prine, Linda
    AMERICAN FAMILY PHYSICIAN, 2023, 108 (05) : 519 - 522
  • [20] Client-reported quality of facility-managed medication abortion compared with pharmacy-sourced self-managed abortion in Bangladesh
    Jacobson, Laura E.
    Baum, Sarah E.
    Pearson, Erin
    Chowdhury, Rezwana
    Chakraborty, Nirali M.
    Goodman, Julia M.
    Gerdts, Caitlin
    Darney, Blair G.
    BMJ SEXUAL & REPRODUCTIVE HEALTH, 2024, 50 (01) : 33 - 42